Safety Outcomes / Diabetes

((A-304)) (A-304) Glucagon-like Peptide-1 Receptor Agonists vs. Sodium-glucose Cotransporter 2 Inhibitors and Risk for Dementia in Individuals with Diabetes: A Propensity-weighted, Population-based Cohort Study.

((A-305)) (A-305) Association of Glucagon-like Peptide-1 Receptor Agonists with Acute Pancreatitis and Biliary Disease in Individuals with Diabetes and Obesity: A Propensity-weighted, Population-based Cohort Study.

((A-306)) (A-306) Comparison of the Pneumonia Risk Between GLP-1RAs and DPP4 Inhibitors in Taiwan

((A-307)) (A-307) The Effectiveness on Diabetic Retinopathy Between GLP-1 Receptor Agonists and DPP-4 Inhibitors in Taiwan

((A-308)) (A-308) Risk of pre-sarcopenia and SGLT2 inhibitors in young adults with type 2 diabetes: A nationwide cohort study

((A-309)) (A-309) Glucagon-like peptide-1 Receptor Agonists and the Risk of Gastroesophageal Reflux Disease in Patients with Type 2 Diabetes

((A-310)) (A-310) Serum 25-Hydroxyvitamin D Levels and Risk of Diabetes Complications in Sulfonylurea Users: A Linked Database of Kangbuk Samsung Health Study and Nationwide Claims Data

((A-311)) (A-311) High Throughput Screening for GLP-1 RA-Induced Prescribing Cascades among Older Adults with and without Obstructive Sleep Apnea

((A-312)) (A-312) Study design and comparator choices in evaluating the risk of suicidal ideation and suicidality with semaglutide: A real-world study

((A-313)) (A-313) Post-authorization Safety Study to Assess the Risk of Diabetic Ketoacidosis among Type 2 Diabetes Mellitus Patients Treated with Ertugliflozin Compared to Patients Treated with Other Antihyperglycemic Agents

((A-314)) (A-314) Association between depression and use of sodium-glucose cotransporter-2 inhibitors using target trial emulation: population-based cohort study

((A-315)) (A-315) Risk of Incident Inflammatory Bowel Disease in New Users of Dipeptidyl Peptidase 4 Inhibitors, Sodium Glucose Cotransporter 2 Inhibitors, or Sulfonylurea in the U.S. Food and Drug Administration’s Sentinel System

((A-316)) (A-316) Risk of Diabetic Ketoacidosis Across Stages of Chronic Kidney Disease in Patients with Type 1 Diabetes in the U.S. Food and Drug Administration’s Sentinel System

((A-317)) (A-317) Investigating the association between glucagon-like peptide 1 receptor agonists and obstructive sleep apnea incidence using United States Medicare data 2007-2019

((C-241)) (C-241) A Retrospective Cohort Study of Sarcopenia in Patients with Type 2 Diabetes Mellitus treated with SGLT2 Inhibitors and Other Antihyperglycemic Agents